Evidence map›Paper›PMID 35207671›Full record

ReviewJournal of personalized medicine2022

Personalized Management of Myocarditis and Inflammatory Cardiomyopathy in Clinical Practice.

Agata Tymińska, Krzysztof Ozierański, Aleksandra Skwarek, Agnieszka Kapłon-Cieślicka, Anna Baritussio, Marcin Grabowski, Renzo Marcolongo, Alida Lp Caforio

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of personalized medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. The Role of Molecular Imaging in Personalized Medicine.Journal of personalized medicine · 2023
    Review
  14. Article
  15. The Role of MicroRNAs in Myocarditis-What Can We Learn from Clinical Trials?International journal of molecular sciences · 2022
    Review
  16. Review
  17. Role of Endomyocardial Biopsy in Diagnostics of Myocarditis.Diagnostics (Basel, Switzerland) · 2022
    Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Agata TymińskaFirst Department of Cardiology, Medical University of Warsaw, 1a Banacha St., 02-097 Warsaw, Poland.ORCID 0000-0003-1381-302X
Krzysztof OzierańskiFirst Department of Cardiology, Medical University of Warsaw, 1a Banacha St., 02-097 Warsaw, Poland.ORCID 0000-0002-3848-0922
Aleksandra SkwarekFirst Department of Cardiology, Medical University of Warsaw, 1a Banacha St., 02-097 Warsaw, Poland.
Agnieszka Kapłon-CieślickaFirst Department of Cardiology, Medical University of Warsaw, 1a Banacha St., 02-097 Warsaw, Poland.
Anna BaritussioDivision of Cardiology, Department of Cardiac, Thoracic and Vascular Sciences and Public Health, University of Padova, 2-35128 Padova, Italy.
Marcin GrabowskiFirst Department of Cardiology, Medical University of Warsaw, 1a Banacha St., 02-097 Warsaw, Poland.ORCID 0000-0003-3306-0301
Renzo MarcolongoDivision of Cardiology, Department of Cardiac, Thoracic and Vascular Sciences and Public Health, University of Padova, 2-35128 Padova, Italy.
Alida Lp CaforioDivision of Cardiology, Department of Cardiac, Thoracic and Vascular Sciences and Public Health, University of Padova, 2-35128 Padova, Italy.ORCID 0000-0002-4901-5655
Medical University of Warsaw · PLUniversity of Padua · IT

Funding

Servier Scientific Grant from the Polish Cardiac Society unconditionally founded by Servier
6 · The paper itself

Abstract

Myocarditis is an inflammatory heart disease induced by infectious and non-infectious causes frequently triggering immune-mediated pathologic mechanisms leading to myocardial damage and dysfunction. In approximately half of the patients, acute myocarditis resolves spontaneously while in the remaining cases, it may evolve into serious complications including inflammatory cardiomyopathy, arrhythmias, death, or heart transplantation. Due to the large variability in clinical presentation, unpredictable course of the disease, and lack of established causative treatment, myocarditis represents a challenging diagnosis in modern cardiology. Moreover, an increase in the incidence of myocarditis and inflammatory cardiomyopathy has been observed in recent years. However, there is a growing potential of available non-invasive diagnostic methods (biomarkers, serum anti-heart autoantibodies (AHA), microRNAs, speckle tracking echocardiography, cardiac magnetic resonance T1 and T2 tissue mapping, positron emission tomography), which may refine the diagnostic workup and/or noninvasive follow-up. Personalized management should include the use of endomyocardial biopsy and AHA, which may allow the etiopathogenetic subsets of myocarditis (infectious, non-infectious, and/or immune-mediated) to be distinguished and implementation of disease-specific therapies. In this review, we summarize current knowledge on myocarditis and inflammatory cardiomyopathy, and outline some practical diagnostic, therapeutic, and follow-up algorithms to facilitate comprehensive individualized management of these patients.

Indexed as

anti-heart autoantibodiesendomyocardial biopsyheart failureimmunosuppressive treatmentindividualized therapyinflammationpersonalized medicine

Identifiers

PMID35207671
PMCPMC8874629
OpenAlexW4210395213

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.